COMMUNIQUÉS West-GlobeNewswire

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")
28/03/2018
REGULATED INFORMATION GHENT, Belgium, 28 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]
Kiadis Pharma on track with European regulatory review for ATIR101
28/03/2018
Kiadis Pharma on track with European regulatory review for ATIR101 Responses submitted to EMA Day 120 list of questions Amsterdam, The Netherlands, March 28, 2018 - Kiadis Pharma N.V. ("Kiadis Pharma" or the "Company [...]
Arcturus Therapeutics Initiates Lawsuit Against Joseph E. Payne to Protect the Interests of Arcturus Shareholders
28/03/2018
Complaint Details Extensive Misconduct by Mr. Payne during Tenure as CEO Cites Mr. Payne’s Self-Dealing and Inappropriate Business Conflicts of Interest SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Arcturus [...]
REVA Announces First Implant of the Fantom Encore Bioresorbable Scaffold in Switzerland
28/03/2018
SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the first implant of the Fantom [...]
EDAP TMS SA : EDAP Reports 2017 Annual Results
27/03/2018
2017 Highlights 2017 revenue on par with 2016; lower HIFU capital equipment sales offset by double-digit HIFU treatment revenue growth CMS issued C-Code allocation for reimbursement of HIFU for prostate tissue ablation [...]
IntelGenx Announces Update on Private Placement and Proposed LaboVal Acquisition
27/03/2018
SAINT LAURENT, Quebec, March 27, 2018 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX-V: IGX ) (OTCQX:IGXT) (the “Company” or “IntelGenx”) announces that, due to market conditions, it will not be proceeding with [...]
Apricus Biosciences Announces Proposed Public Offering
27/03/2018
SAN DIEGO, March 27, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has commenced a [...]
Dyadic International Announces 2017 Year End Results and Recent Developments
27/03/2018
$49.1 million of cash, cash equivalents and investment securities as of December 31, 2017 Successfully executed two funded collaborations in 2017 and signed three new collaborations in 2018 Early data generated from our [...]
Amarin Commemorates National Triglycerides Day on March 28
27/03/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, March 27, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2017 Financial Results on April 3, 2018
27/03/2018
HOUSTON, March 27, 2018 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH ), a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of [...]
Aptose Reports Results for the Fourth Quarter and Year Ended December 31, 2017
27/03/2018
SAN DIEGO and TORONTO, March 27, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO ) (TSX: APS ), a clinical-stage company developing highly differentiated therapeutics that [...]
BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018
27/03/2018
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI ), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the [...]
Leap Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
27/03/2018
CAMBRIDGE, Mass., March 27, 2018 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (NASDAQ: LPTX ), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of a [...]
GeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatment
27/03/2018
DOWNERS GROVE, Ill., March 27, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration has granted orphan-drug designation to GeneTx Biotherapeutics LLC’s GTX-101 for the treatment of Angelman syndrome, a rare [...]
Bavarian Nordic to Present at Needham & Company's 17th Annual Healthcare Conference in New York City
27/03/2018
COPENHAGEN, Denmark - March 27, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Paul Chaplin, President & Chief Executive Officer will provide a corporate presentation at Needham & [...]
Ossur Hf : Registration of capital reduction of 6,354,662 shares completed
27/03/2018
Announcement no. 24/2018 Reykjavik, 27 March 2018 Registration of capital reduction of 6,354,662 shares completed Reference is made to the Company's announcement no. 17/2018 published on 8 March 2018. The capital [...]
OSE Immunotherapeutics Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
27/03/2018
NANTES, France, March 27, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173) (Mnémo:OSE), today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences [...]
GUERBET : 2017 annual results
27/03/2018
> EBITDA increased by 22.4% to €130 million > Net income up 60% at €46.2 million > Ongoing debt reduction (leverage ratio of 2.1) Villepinte, March 27, 2018 - Guerbet (FR0000032526 GBT), a global specialist in [...]
GUERBET : Résultats annuels 2017
27/03/2018
> EBITDA en progression de 22,4% à 130 M€ > Résultat net en augmentation de 60% à 46,2 M€ > Poursuite du désendettement (ratio de levier de 2,1) Villepinte, le 27 mars 2018 - Guerbet (FR0000032526 GBT), [...]

Pages